Search - tctmd.com

Displaying 241 - 260 of 320

Sort: Relevancy | Date

Presentation ACC 2013

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Presenter: Ian T. Meredith

March 09, 2013

News Conference News ACC 2013

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

Jason Kahn

March 09, 2013

Presentation TCT 2013

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Presenter: Peter Smits, A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet

January 31, 2013

Presentation TCT 2013

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel / Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results from the SEEDS Study

Presenter: Bo Xu, Yuejin Yang, Yaling Han, Bao Li, Qiang Liu, Guoying Zhu, Junyu Cui, Lang Li, Shuzheng Lu

January 31, 2013

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Jason Kahn

January 22, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Daily News

EES Outperform First-Generation DES in Treatment of CTOs

L.A. McKeown

December 27, 2012

News Daily News

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Caitlin E. Cox

December 26, 2012

News Daily News

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Caitlin E. Cox

December 26, 2012

Presentation

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

Presenter: K. W. Park

December 25, 2012

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

Presentation TCT 2012

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Presenter: James Hermiller Jr

October 23, 2012

News Daily News

Stent Fractures Persist Among Newer-Generation Devices

Jason Kahn

October 02, 2012

News Daily News

Las Fracturas del Stent Persisten en los Dispositivos de Nueva Generación

Jason Kahn

October 02, 2012

News Daily News

Un Registro Coreano Confirma la Superioridad de los Stents liberadores de Everolimus sobre los de Zotarolimus

September 19, 2012

News Daily News

Korean Registry Confirms Edge of Everolimus- Over Zotarolimus-Eluting Stents

September 19, 2012

News Daily News

SORT OUT IV: Xience Holds Edge Over Cypher for Preventing Stent Thrombosis

Yael L. Maxwell

September 07, 2012

News Daily News

SORT OUT IV: El Xience Aguanta el Tirón del Cypher en la Prevención de la Trombosis del Stent

Yael L. Maxwell

September 07, 2012

News Conference News ESC 2012

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Caitlin E. Cox

August 29, 2012

News Industry News

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

August 20, 2012

Advertisement

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel / Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results from the SEEDS Study

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

EES Outperform First-Generation DES in Treatment of CTOs

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Stent Fractures Persist Among Newer-Generation Devices

Las Fracturas del Stent Persisten en los Dispositivos de Nueva Generación

Un Registro Coreano Confirma la Superioridad de los Stents liberadores de Everolimus sobre los de Zotarolimus

Korean Registry Confirms Edge of Everolimus- Over Zotarolimus-Eluting Stents

SORT OUT IV: Xience Holds Edge Over Cypher for Preventing Stent Thrombosis

SORT OUT IV: El Xience Aguanta el Tirón del Cypher en la Prevención de la Trombosis del Stent

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content